相关实验视频

Updated: Jun 13, 2025

Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice

Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice

Published on: December 4, 2020

与empagliflozin相关的优糖性糖尿病酸性脂肪酸症被尿路感染掩盖

Sukhjinder Chauhan¹, Victoria Diaz¹, Ikechukwu R Ogbu²

¹Internal Medicine, Mountainview Hospital, Las Vegas, USA.

|September 9, 2024

概括

-葡萄糖共载体2 (SGLT2) 抑制剂有助于慢性病和心力衰竭患者. 这一案例突出了罕见但严重的euglycemic糖尿病酸症 (euDKA) 风险,强调了及时诊断和管理.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
内分泌学在内分泌学.
心脏病学心脏病学

背景情况:

-葡萄糖共载体2 (SGLT2) 抑制剂在治疗2型糖尿病 (T2DM),慢性病 (CKD) 和充血性心力衰竭 (CHF) 中有效.
这些药物可以降低心血管和整体死亡率,但会带来不良事件的风险,如euglycemic糖尿病酸症 (euDKA),尿路感染 (UTI) 和真菌感染.

研究的目的:

报告患者在接受SGLT2抑制剂治疗时同时出现eudka和尿路感染的病例.
要强调早期识别和管理SGLT2抑制剂相关的eudka的重要性.

主要方法:

病例报告详细介绍了90岁男性缺血性心肌病和T2DM的临床表现,诊断工作和治疗.
审查患者的病史,药物治疗方案 (包括SGLT2抑制剂) 和事件期间的实验室发现.

主要成果:

在接受SGLT2抑制剂治疗期间,患者出现了eudka和尿路感染.
立即停止使用SGLT2抑制剂并开始胰岛素输液治疗,导致危及生命的eudka.

结论:

尽管SGLT2抑制剂有好处,但即使没有严重的高血糖症,也可能导致eudka等严重并发症.
在服用SGLT2抑制剂的患者中对eudka的警,特别是那些同时感染或其他压力因素的患者,对于及时干预和改善结果至关重要.

关键词:

阴离子间隙代谢酸性化 dka dka 的意思是什么达卡协议是关于达卡协议的.欧德卡 (Eudka) 是一个优格莱西米克酸性化症胰岛素输注注注入胰岛素输注.sglt-2 抑制剂的使用.sglt2 eudkaka 在线观看在线观看

更多相关视频

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis

Published on: July 18, 2017

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Diabetes: Symptoms, Diagnosis, and Complications

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...